“Clinical response to Rifaximin amongst irritable bowel syndrome (IBS) patients at tertiary level hospital in Nepal” (2024) Journal of Patan Academy of Health Sciences, 11(1), pp. 21–26. doi:10.3126/jpahs.v11i1.65652.